ArticleBMC cancer2015
Low expression levels of hepsin and TMPRSS3 are associated with poor breast cancer survival.
Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Pan-cancer expression, methylation, and prognostic significance of α7 nicotinic acetylcholine receptor in tumor immunology.Biochemistry and biophysics reports · 2026Article
- Analysis of the pharmacological mechanisms of Xiaoyao pill in breast cancer treatment.Annals of medicine and surgery (2012) · 2025Article
- Thyroid hormone suppresses cell growth by regulating CDK2 and cyclin E1 expression via Hepsin.American journal of cancer research · 2025Article
- LINC00651, A Long Non-coding RNA, Acts as a Catalyst in the Progression of Breast Cancer by Promoting Proliferation, Migration, and Invasion.Current medicinal chemistry · 2025Article
- A multi-tissue, splicing-based joint transcriptome-wide association study identifies susceptibility genes for breast cancer.American journal of human genetics · 2024Article
- Exploring the Clinical Implications of RPL3 Presence in BRCA-Associated Cancers: Unraveling the Interplay With Cancer Immunity.Clinical Medicine Insights. Oncology · 2024Article
- KIAA1429 facilitates progression of hepatocellular carcinoma by modulating m6A levels in HPN.Heliyon · 2023Article
- Implication of Hepsin from Primary Tumor in the Prognosis of Colorectal Cancer Patients.Cancers · 2022Article
- Clinical Significance of Hepsin and Underlying Signaling Pathways in Prostate Cancer.Biomolecules · 2022Review
- Analysis of Pan-Cancer Revealed the Immunological and Prognostic Potential of CBX3 in Human Tumors.Frontiers in medicine · 2022Article
- Aberrant expression of WDR4 affects the clinical significance of cancer immunity in pan-cancer.Aging · 2021Article
- L1CAM, CA9, KLK6, HPN, and ALDH1A1 as Potential Serum Markers in Primary and Metastatic Colorectal Cancer Screening.Diagnostics (Basel, Switzerland) · 2020Article
- Cell surface-anchored serine proteases in cancer progression and metastasis.Cancer metastasis reviews · 2019Review
- Excess hepsin proteolytic activity limits oncogenic signaling and induces ER stress and autophagy in prostate cancer cells.Cell death & disease · 2019Article
- COPB2 is up-regulated in breast cancer and plays a vital role in the metastasis via N-cadherin and Vimentin.Journal of cellular and molecular medicine · 2019Article
- Article
- LncRNA CCND2-AS1 is up-regulated and regulates proliferation, migration, and invasion in breast cancer.International journal of clinical and experimental pathology · 2018Article
- Expression levels and clinical significance of hepsin and HMGB1 proteins in cervical carcinoma.Oncology letters · 2017Article
- Transposable Elements in Human Cancer: Causes and Consequences of Deregulation.International journal of molecular sciences · 2017Review
- High Hepsin expression predicts poor prognosis in Gastric Cancer.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepsin, (also called TMPRSS1) and TMPRSS3 are type II transmembrane serine proteases (TTSPs) that are involved in cancer progression. TTSPs can remodel extracellular matrix (ECM) and, when dysregulated, promote tumor progression and metastasis by inducing defects in basement membrane and ECM molecules. This study investigated whether the gene and protein expression levels of these TTSPs were associated with breast cancer characteristics or survival.
methodsImmunohistochemical staining was used to evaluate hepsin levels in 372 breast cancer samples and TMPRSS3 levels in 373 samples. TMPRSS1 mRNA expression was determined in 125 invasive and 16 benign breast tumor samples, and TMPRSS3 mRNA expression was determined in 167 invasive and 23 benign breast tumor samples. The gene and protein expression levels were analyzed for associations with breast cancer-specific survival and clinicopathological parameters.
resultsLow TMPRSS1 and TMPRSS3 mRNA expression levels were independent prognostic factors for poor breast cancer survival during the 20-year follow-up (TMPRSS1, P = 0.023; HR, 2.065; 95 % CI, 1.106-3.856; TMPRSS3, P = 0.013; HR, 2.106; 95 % CI, 1.167-3.800). Low expression of the two genes at the mRNA and protein levels associated with poorer survival compared to high levels (log rank P-values 0.015-0.042). Low TMPRSS1 mRNA expression was also an independent marker of poor breast cancer prognosis in patients treated with radiotherapy (P = 0.034; HR, 2.344; 95 % CI, 1.065-5.160). Grade III tumors, large tumor size, and metastasis were associated with low mRNA and protein expression levels.
conclusionsThe results suggest that the TTSPs hepsin and TMPRSS3 may have similar biological functions in the molecular pathology of breast cancer. Low mRNA and protein expression levels of the studied TTSPs were prognostic markers of poor survival in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.